Who are FCN-437c,Fulvestrant,Goserelin acetate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fcn-437c-fulvestrant-goserelin-acetate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

FCN-437c,Fulvestrant,Goserelin acetate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FCN-437c,Fulvestrant,Goserelin acetate (FCN-437c,Fulvestrant,Goserelin acetate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen receptor degrader + GnRH agonist combination. Area: Oncology.

phase 3 Estrogen receptor degrader + GnRH agonist combination Estrogen receptor (ER); GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FCN-437c,Fulvestrant,Goserelin acetate (FCN-437c,Fulvestrant,Goserelin acetate) — Ahon Pharmaceutical Co., Ltd.. This combination therapy uses an estrogen receptor degrader (fulvestrant) and a gonadotropin-releasing hormone agonist (goserelin) to suppress estrogen signaling in hormone receptor-positive breast cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FCN-437c,Fulvestrant,Goserelin acetate TARGET	FCN-437c,Fulvestrant,Goserelin acetate	Ahon Pharmaceutical Co., Ltd.	phase 3	Estrogen receptor degrader + GnRH agonist combination	Estrogen receptor (ER); GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen receptor degrader + GnRH agonist combination class)

Ahon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FCN-437c,Fulvestrant,Goserelin acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/fcn-437c-fulvestrant-goserelin-acetate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab